Robert C. Bast Jr.
Robert C. Bast Jr. | |
|---|---|
| Born | December 8, 1943 |
| Alma mater | |
| Scientific career | |
| Institutions | University of Texas MD Anderson Cancer Center |
| Website | |
Robert Clinton Bast Jr., (born December 8, 1943) is an American physician-scientist who is currently Vice President for Translational Research at the University of Texas M.D. Anderson Cancer Center.[1] Bast is best known for the discovery of CA125, a serum biomarker for ovarian cancer that has contributed to the care of ovarian cancer patients worldwide.[2] His research spans early detection, enhancing chemotherapy and understanding regulation of dormancy and the role of autophagy in breast and ovarian cancer.
References
[edit]- ^ "Robert C. Bast". MD Anderson Cancer Center. Retrieved 2019-05-20.
- ^ "Robert C. Bast, Jr., M.D." NFCR. Retrieved 2019-05-20.
| International | |
|---|---|
| National | |
| Academics | |
| Other | |
